Let the insurers pay!

That's the word from a new survey by Kaiser Family Foundation. Respondents were asked to share their views on the emerging line of weight-loss drugs flowing from pharmaceutical labs. They are curious about them, want to know more, and ultimately want insurance companies to cover the cost to the consumer as the pills and injectable products make their way into the marketplace.

The poll was designed to gauge "the public's interest in using prescription drugs to lose weight as a relatively new class of drugs, initially approved to treat diabetes, is garnering attention for their potential to aid weight loss," KFF said. Among these new diabetes/weight fighters are Ozempic, Wegovy, and Mounjaro. With health care providers and plan sponsors becoming increasingly focused on treating chronic illnesses such as diabetes, a product that addresses weight loss as well has become much ballyhooed due to the U.S. obesity crisis.

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Dan Cook

Dan Cook is a journalist and communications consultant based in Portland, OR. During his journalism career he has been a reporter and editor for a variety of media companies, including American Lawyer Media, BusinessWeek, Newhouse Newspapers, Knight-Ridder, Time Inc., and Reuters. He specializes in health care and insurance related coverage for BenefitsPRO.